Patel D, Kell A, Simard B, Xiang B, Lin HY, Tian G. The cell labeling efficacy, cytotoxicity and relaxivity of copper-activated MRI/PET imaging contrast agents. Biomaterials 2011; 32(4): 1167–1176.
Bouziotis P, Psimadas D, Tsotakos T, Stamopoulos D, Tsoukalas C. Radiolabeled iron oxide nanoparticles as dual-modality SPECT/MRI and PET/MRI agents. Curr Top Med Chem 2012; 12(23): 2694–2702.
Schlemmer H-PW, Pichler BJ, Schmand M, Burbar Z, Michel C, Ladebeck R, Jattke K, Townsend D, Nahmias C, Jacob PK. Simultaneous MR/PET Imaging of the Human Brain: Feasibility Study 1. Radiology 2008; 248(3): 1028–1035.
Kurihara H, Shimizu C, Miyakita Y, Yoshida M, Hamada A, Kanayama Y, Yonemori K, Hashimoto J, Tani H, Kodaira M. Molecular imaging using PET for breast cancer. Breast Cancer 2016; 23(1): 24–32.
Martí-Bonmatí L, Sopena R, Bartumeus P, Sopena P. Multimodality imaging techniques. Contrast Media Mol I 2010; 5(4): 180–189.
Sauter AW, Wehrl HF, Kolb A, Judenhofer MS, Pichler BJ. Combined PET/MRI: one step further in multimodality imaging. Trends Mol Med 2010; 16(11): 508–515.
Pichler BJ, Kolb A, Nägele T, Schlemmer H-P. PET/MRI: paving the way for the next generation of clinical multimodality imaging applications. J Nucl Med 2010; 51(3): 333–336.
Fraum TJ, Fowler KJ, McConathy J, Parent EE, Dehdashti F, Grigsby PW, Siegel BA. PET/MRI for the body imager: abdominal and pelvic oncologic applications. Abdom Imaging 2015; 40(6): 1387–1404.
Jarrett BR, Br G, Kukis DL, Louie AY. Synthesis of 64Cu-labeled magnetic nanoparticles for multimodal imaging. Bioconjug Chem 2008; 19(7): 1496–1504.
Nappi C, Altiero M, Imbriaco M, Nicolai E, Giudice CA, Aiello M, Diomiaiuti CT, Pisani A, Spinelli L, Cuocolo A. First experience of simultaneous PET/MRI for the early detection of cardiac involvement in patients with Anderson-Fabry disease. Eur J Nucl Med Mol Imag 2015; 42(7): 1025–1031.
Schulz V, Torres-Espallardo I, Renisch S, Hu Z, Ojha N, Börnert P, Perkuhn M, Niendorf T, Schäfer W, Brockmann H. Automatic, three-segment, MR-based attenuation correction for whole-body PET/MR data. Eur J Nucl Med Mol Imag 2011; 38(1): 138–152.
Werner MK, Schmidt H, Schwenzer NF. MR/PET: a new challenge in hybrid imaging. Am J Roentgenol 2012; 199(2): 272–277.
Schlemmer H-P, Pichler BJ, Krieg R, Heiss W-D. An integrated MR/PET system: prospective applications. Abdom Imaging 2009; 34(6): 668–674.
Paldino MJ, Barboriak DP. Fundamentals of quantitative dynamic contrast-enhanced MR imaging. Magn Reson Imaging Clin N Am 2009; 17(2): 277–289.
Thoeny HC, Ross BD. Predicting and monitoring cancer treatment response with diffusion-weighted MRI. J Magn Reson Imaging 2010; 32(1): 2–16.
Koh D-M, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. Am J Roentgenol 2007; 188(6): 1622–1635.
von Schulthess GK, Schlemmer H-PW. A look ahead: PET/MR versus PET/CT. Eur J Nucl Med Mol Imag 2009; 36(1): 3–9.
Marzola P, Osculati F, Sbarbati A. High field MRI in preclinical research. Eur J Radiol 2003; 48(2): 165–170.
Antoch G, Bockisch A. Combined PET/MRI: a new dimension in whole-body oncology imaging? Eur J Nucl Med Mol Imag 2009; 36(1): 113–120.
Buchbender C, Heusner TA, Lauenstein TC, Bockisch A, Antoch G. Oncologic PET/MRI, part 1: tumors of the brain, head and neck, chest, abdomen, and pelvis. J Nucl Med 2012; 53(6): 928–938.
Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, de la Rosette J, Weissleder R. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. New Engl J Med 2003; 348(25): 2491–2499.
Nekolla SG, Martinez-Moeller A, Saraste A. PET and MRI in cardiac imaging: from validation studies to integrated applications. Eur J Nucl Med Mol Imag 2009; 36(1): 121–130.
Herholz K. PET studies in dementia. Ann Nucl Med 2003; 17(2): 79–89.
Koepp MJ, Woermann FG. Imaging structure and function in refractory focal epilepsy. Lancet Neurol 2005; 4(1): 42–53.
Antoch G, Bockisch A. Combined PET/MRI: a new dimension in whole-body oncology imaging? Eur J Nucl Med Mol Imaging 2009; 36(1): 113–120.
Teixeira SR, Martinez-Rios C, Hu L, Bangert BA. Clinical Applications of Pediatric Positron Emission Tomography-Magnetic Resonance Imaging. Paper presented at: Seminars in roentgenology, 2014.
Vandenberghe S, Marsden PK. PET-MRI: a review of challenges and solutions in the development of integrated multimodality imaging. Phys Med Biol 2015; 60(4): R115.
Zaidi H, Montandon M-L, Slosman DO. Magnetic resonance imaging-guided attenuation and scatter corrections in three-dimensional brain positron emission tomography. Med Phys 2003; 30(5): 937–948.
Salomon A, Goedicke A, Schweizer B, Aach T, Schulz V. Simultaneous reconstruction of activity and attenuation for PET/MR. Medical Imaging, IEEE Transactions on 2011; 30(3): 804–813.
Renker D. New trends on photodetectors. Nucl Instrum Meth A 2007; 571(1): 1–6.
Liang H-D, Blomley MJK. The role of ultrasound in molecular imaging. Brit J Radiol 2003; 76(suppl_2): S140–S150.
Vandenberghe S, Marsden PK. PET-MRI: a review of challenges and solutions in the development of integrated multimodality imaging. Phys Med Biol 2015; 60(4): R115.
Yankeelov TE, Peterson TE, Abramson RG, Garcia-Izquierdo D, Arlinghaus LR, Li X, Atuegwu NC, Catana C, Manning HC, Fayad ZA. Simultaneous PET–MRI in oncology: a solution looking for a problem? Magn Reson Imaging 2012; 30(9): 1342–1356.
Catana C, Guimaraes AR, Rosen BR. PET and MR imaging: the odd couple or a match made in heaven? J Nucl Med 2013; 54(5): 815–824.
Vriens D, Visser EP, de Geus-Oei L-F, Oyen WJ. Methodological considerations in quantification of oncological FDG PET studies. Eur J Nucl Med Mol Imag 2010; 37(7): 1408–1425.
Baumgartner CF, Kolbitsch C, Balfour DR, Marsden PK, McClelland JR, Rueckert D, King AP. High-resolution dynamic MR imaging of the thorax for respiratory motion correction of PET using groupwise manifold alignment. Med Image Anal 2014; 18(7): 939–952.
Fayad H, Monnier F, Odille F, Felblinger J, Lamare F, Visvikis D. Respiratory and cardiac motion correction in dual gated PET/MR imaging. EJNMMI Physics 2015; 2(Suppl 1): A43.
Madru R, Tran TA, Axelsson J, Ingvar C, Bibic A, Ståhlberg F, Knutsson L, Strand S-E. 68Ga-labeled superparamagnetic iron oxide nanoparticles (SPIONs) for multi-modality PET/MR/Cherenkov luminescence imaging of sentinel lymph nodes. Am J Nucl Med Mol Imaging 2014; 4(1): 60.
Madru R, Kjellman P, Olsson F, Wingårdh K, Ingvar C, Ståhlberg F, Olsrud J, Lätt J, Fredriksson S, Knutsson L. 99mTc-labeled superparamagnetic iron oxide nanoparticles for multimodality SPECT/MRI of sentinel lymph nodes. J Nucl Med 2012; 53: 459–463.
Thorek DL, Ulmert D, Diop N-FM, Lupu ME, Doran MG, Huang R, Abou DS, Larson SM, Grimm J. Non-invasive mapping of deep-tissue lymph nodes in live animals using a multimodal PET/MRI nanoparticle. Nat Commun 2014; 5: 3097.
Natarajan A, Gruettner C, Ivkov R, DeNardo GL, Mirick G, Yuan A, Foreman A, DeNardo SJ. NanoFerrite Particle Based Radioimmunonanoparticles: Binding affinity and in vivo pharmacokinetics. Bioconjug Chem 2008; 19: 1211–1218.
Torres Martin de Rosales R, Tavaré R, Glaria A, Varma G, Protti A, Blower PJ. 99mTc-bisphosphonate-iron oxide nanoparticle conjugates for dual-modality biomedical imaging. Bioconj Chem 2011; 22(3): 455–465.
Liu T, Shi S, Liang C, Shen S, Cheng L, Wang C, Song X, Goel S, Barnhart TE, Cai W. Iron Oxide Decorated MoS2 Nanosheets with Double PEGylation for Chelator-Free Radiolabeling and Multimodal Imaging Guided Photothermal Therapy. ACS Nano 2015; 9: 950–960.
Hoffman D, Sun M, Yang L, McDonagh PR, Corwin F, Sundaresan G, Wang L, Vijayaragavan V, Thadigiri C, Lamichhane N. Intrinsically radiolabelled [59Fe]-SPIONs for dual MRI/radionuclide detection. Am J Nucl Med Mol Imaging 2014; 4: 548.
Wang H, Kumar R, Nagesha D, Duclos RI, Sridhar S, Gatley SJ. Integrity of 111 In-radiolabeled superparamagnetic iron oxide nanoparticles in the mouse. Nucl Med Biol 2015; 42: 65–70.
Truillet C, Bouziotis P, Tsoukalas C, Brugière J, Martini M, Sancey L, Brichart T, Denat F, Boschetti F, Darbost U. Ultrasmall particles for Gd-MRI and 68Ga-PET dual imaging. Contrast Media Mol Imaging 2015; 10(4): 309–319.
Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Del Rev 2011; 63: 136–151.
Zhao F, Zhao Y, Liu Y, Chang X, Chen C, Zhao Y. Cellular uptake, intracellular trafficking, and cytotoxicity of nanomaterials. Small 2011; 7: 1322–1337.
Yang X, Hong H, Grailer JJ, Rowland IJ, Javadi A, Hurley SA, Xiao Y, Yang Y, Zhang Y, Nickles RJ. cRGD-functionalized, DOX-conjugated, and 64 Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging. Biomaterials 2011; 32(17): 4151–4160.
Lee H-Y, Li Z, Chen K, Hsu AR, Xu C, Xie J, Sun S, Chen X. PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)–conjugated radiolabeled iron oxide nanoparticles. J Nucl Med 2008; 49(8): 1371–1379.
Tsiapa I, Efthimiadou EK, Fragogeorgi E, Loudos G, Varvarigou AD, Bouziotis P, Kordas GC, Mihailidis D, Nikiforidis GC, Xanthopoulos S. 99 m Tc-labeled aminosilane-coated iron oxide nanoparticles for molecular imaging of ανβ3-mediated tumor expression and feasibility for hyperthermia treatment. J Colloid Interf Sci 2014; 433: 163–175.
Lee J, Lee TS, Ryu J, Hong S, Kang M, Im K, Kang JH, Lim SM, Park S, Song R. RGD Peptide–Conjugated Multimodal NaGdF4: Yb3+/Er3+ Nanophosphors for Upconversion Luminescence, MR, and PET Imaging of Tumor Angiogenesis. J Nucl Med 2013; 54: 96–103.
Lin X, Xie J, Niu G, Zhang F, Gao H, Yang M, Quan Q, Aronova MA, Zhang G, Lee S, Leapman R, Chen X. Chimeric ferritin nanocages for multiple function loading and multimodal imaging. Nano Lett 2011; 11: 814–819.
Deng S, Zhang W, Zhang B, Hong R, Chen Q, Dong J, Chen Y, Chen Z, Wu Y. Radiolabeled cyclic arginine-glycine-aspartic (RGD)-conjugated iron oxide nanoparticles as single-photon emission computed tomography (SPECT) and magnetic resonance imaging (MRI) dual-modality agents for imaging of breast cancer. J Nanopart Res 2015; 17: 1–11.
Ko HY, Choi K-J, Lee CH, Kim S. A multimodal nanoparticle-based cancer imaging probe simultaneously targeting nucleolin, integrin α v β 3 and tenascin-C proteins. Biomaterials 2011; 32: 1130–1138.
Misri R, Meier D, Yung AC, Kozlowski P, Häfeli UO. Development and evaluation of a dual-modality (MRI/SPECT) molecular imaging bioprobe. Nanomed Nanotechnol Biol Med 2012; 8: 1007–1016.
Xie J, Chen K, Huang J, Lee S, Wang J, Gao J, Li X, Chen X. PET/NIRF/MRI Triple Functional Iron Oxide Nanoparticles. Biomaterials 2010; 31: 3016–3022.
Desai MP, Labhasetwar V, Amidon GL, Levy RJ. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res 1996; 13: 1838–1845.
Prabha S, Zhou W-Z, Panyam J, Labhasetwar V. Size-dependency of nanoparticle-mediated gene transfection: studies with fractionated nanoparticles. Int J Pharm 2002; 244: 105–115.
Natarajan A, Xiong C-Y, Gruettner C, DeNardo GL, DeNardo SJ. Development of multivalent radioimmunonanoparticles for cancer imaging and therapy. Cancer Biother Radiopharm 2008; 23: 82–91.
Cui X, Mathe D, Kovács N, Horváth I, Jauregui-Osoro M, Torres Martin de Rosales R, Mullen GE, Wong W, Yan Y, Krüger D. Synthesis, Characterization, and Application of Core–Shell Co0. 16Fe2. 84O4@ NaYF4 (Yb, Er) and Fe3O4@ NaYF4 (Yb, Tm) Nanoparticle as Trimodal (MRI, PET/SPECT, and Optical) Imaging Agents. Bioconjug Chem 2016; 27(2): 319–328.
Li S-D, Huang L. Pharmacokinetics and Biodistribution of Nanoparticles. Mol Pharm 2008; 5: 496–504.
Bumb A, Regino CA, Egen JG, Bernardo M, Dobson PJ, Germain RN, Choyke PL, Brechbiel MW. Trafficking of a dual-modality magnetic resonance and fluorescence imaging superparamagnetic iron oxide-based nanoprobe to lymph nodes. Mol Imaging Biol 2011; 13: 1163–1172.
Reddy ST, Rehor A, Schmoekel HG, Hubbell JA, Swartz MA. In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J Control Release 2006; 112: 26–34.
Sakulkhu U, Mahmoudi M, Maurizi L, Salaklang J, Hofmann H. Protein Corona Composition of Superparamagnetic Iron Oxide Nanoparticles with Various Physico-Chemical Properties and Coatings. Sci Rep 2014; 4: 5020–5029.
Nosrati S, Shanehsazzadeh S, Yousefnia H, Gholami A, Grüttner C, Jalilian A, Hosseini R, Lahooti A. Biodistribution evaluation of 166Ho–DTPA–SPION in normal rats. J Radioanal Nucl Chem 2016; 2016(307): 1559–1566.
Shanehsazzadeh S, Lahooti A. Biodistribution of 80 nm iron oxide nanoparticles labeled with 99mTc in Balb/c mice. Nucl Med Biol 2014; 7: 625.
Shanehsazzadeh S, Oghabian MA, Daha FJ, Amanlou M, Allen BJ. Biodistribution of ultra small superparamagnetic iron oxide nanoparticles in BALB mice. J Radioanal Nucl Chem 2013; 295: 1517–1523.
Shanehsazzadeh S, Gruettner C, Lahooti A, Mahmoudi M, Allen BJ, Ghavami M, Daha FJ, Oghabian MA. Monoclonal antibody conjugated magnetic nanoparticles could target MUC-1-positive cells in vitro but not in vivo. Contrast Media Mol Imaging 2015; 10: 225–236.
Shanehsazzadeh S, Oghabian MA, Lahooti A, Abdollahi M, Haeri SA, Amanlou M, Daha FJ, Allen BJ. Estimated background doses of [67Ga]-DTPA-USPIO in normal Balb/c mice as a potential therapeutic agent for liver and spleen cancers. Nucl Med Commun 2013; 34: 915–925.
Muller RN, Gillis P, Moiny F, Roch A. Transverse relaxivity of particulate MRI contrast media: from theories to experiments. Magn Reson Med 1991; 22: 178–182.
Pinho SL, Laurent S, Rocha J, Roch A, Delville M-H, Mornet S, Carlos LD, Vander Elst L, Muller RN, Geraldes CF. Relaxometric studies of γ-Fe2O3@ SiO2 core shell nanoparticles: when the coating matters. J Phys Chem C 2012; 116: 2285–2291.
Najafian N, Shanehsazzadeh S, Hajesmaeelzadeh F, Lahooti A, Gruettner C, Oghabian M. Effect of Functional Group and Surface Charge of PEG and Dextran-Coated USPIO as a Contrast Agent in MRI on Relaxivity Constant. Appl Magn Reson 2015; 46: 685–692.
Duan H, Kuang M, Wang X, Wang YA, Mao H, Nie S. Reexamining the effects of particle size and surface chemistry on the magnetic properties of iron oxide nanocrystals: new insights into spin disorder and proton relaxivity. J Phys Chem C 2008; 112: 8127–8131.
Branca M, Marciello M, Ciuculescu-Pradines D, Respaud M, del Puerto MM, Serra R, Casanove M-J, Amiens C. Towards MRI T2 contrast agents of increased efficiency. J Magn Magn Mater 2015; 377: 348–353.
Yang M, Fan Q, Zhang R, Cheng K, Yan J, Pan D, Ma X, Lu A, Cheng Z. Dragon fruit-like biocage as an iron trapping nanoplatform for high efficiency targeted cancer multimodality imaging. Biomaterials 2015; 69: 30–37.
Park JC, Yu MK, An GI, Park SI, Oh J, Kim HJ, Kim JH, Wang EK, Hong IH, Ha YS, Choi TH, Jeong KS, Chang Y, Welch MJ, Jon S, Yoo J. Facile preparation of a hybrid nanoprobe for triple-modality optical/PET/MR imaging. Small 2010; 6: 2863–2868.
Monopoli MP, Walczyk D, Campbell A, Elia G, Lynch I, Bombelli FB, Dawson KA. Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. J Am Chem Soc 2011; 133: 2525–2534.
Mahmoudi M, Lynch I, Ejtehadi MR, Monopoli MP, Bombelli FB, Laurent S. Protein-nanoparticle interactions: opportunities and challenges. Chem Rev 2011; 111: 5610–5637.
Zanganeh S, Spitler R, Erfanzadeh M, Alkilany AM, Mahmoudi M. Protein corona: opportunities and challenges. Int J Biochem Cell Biol 2016; 75: 143–147.
Mahmoudi M, Sheibani S, Milani AS, Rezaee F, Gauberti M, Dinarvand R, Vali H. Crucial role of the protein corona for the specific targeting of nanoparticles. Nanomedicine – UK 2015; 10: 215–226.
Mirshafiee V, Mahmoudi M, Lou K, Cheng J, Kraft ML. Protein corona significantly reduces active targeting yield. Chem Commun (Camb) 2013; 49: 2557–2559.
Mahon E, Salvati A, Baldelli Bombelli F, Lynch I, Dawson KA. Designing the nanoparticle-biomolecule interface for ‘targeting and therapeutic delivery’. J Control Release 2012; 161: 164–174.
Mahmoudi M. Protein corona: The golden gate to clinical applications of nanoparticles. Int J Biochem Cell Biol 2016; 75: 141–142.
Monopoli MP, Aberg C, Salvati A, Dawson KA. Biomolecular coronas provide the biological identity of nanosized materials. Nat Nano 2012; 7: 779–786.
Mirshafiee V, Kim R, Park S, Mahmoudi M, Kraft ML. Impact of protein pre-coating on the protein corona composition and nanoparticle cellular uptake. Biomaterials 2016; 75: 295–304.
Palchetti S, Pozzi D, Mahmoudi M, Caracciolo G. Exploitation of nanoparticle-protein corona for emerging therapeutic and diagnostic applications. J Mater Chem B 2016; 4: 4376–4381.
Amiri H, Bordonali L, Lascialfari A, Wan S, Monopoli MP, Lynch I, Laurent S, Mahmoudi M. Protein corona affects the relaxivity and MRI contrast efficiency of magnetic nanoparticles. Nanoscale 2013; 5: 8656–8665.
Hajesmaeelzadeh F, Shanehsazzadeh S, Grüttner C, Daha FJ, Oghabian MA. Effect of coating thickness of iron oxide nanoparticles on their relaxivity in the MRI. Iran J Basic Med Sci 2016; 19: 166–171.
Gessner R, Dayton PA. Advances in Molecular Imaging with Ultrasound. Mol Imaging 2010; 9(3): 117–127.
James ML, Gambhir SS. A molecular imaging primer: modalities, imaging agents, and applications. Physiol Rev 2012; 92(2): 897–965.
Schroeter ML. Optische Bildgebung in der kognitiven Neurowissenschaft, Habilitation Thesis, Universität Leipzig, Germany, 2006.
Boll H, Nittka S, Doyon F, Neumaier M, Marx A, Kramer M, Groden C, Brockmann MA. Micro-CT based experimental liver imaging using a nanoparticulate contrast agent: a longitudinal study in mice. PLoS One 2011; 6(9e25692).
Qin J, Peng C, Zhao B, Ye K, Yuan F, Peng Z, Yang X, Huang L, Jiang M, Zhao Q, Tang G, Lu X. Noninvasive detection of macrophages in atherosclerotic lesions by computed tomography enhanced with PEGylated gold nanoparticles. Int J Nanomed 2014; 9: 5575–5590.
Thomas R, Park I-K, Jeong YY. Magnetic iron oxide nanoparticles for multimodal imaging and therapy of cancer. Int J Mol Sci 2013; 14(8): 15910–15930.
Sharifi S, Seyednejad H, Laurent S, Atyabi F, Saei AA, Mahmoudi M. Superparamagnetic iron oxide nanoparticles for in vivo molecular and cellular imaging. Contrast Media Mol Imaging 2015; 10(5): 329–355.
Boss A, Bisdas S, Kolb A, Hofmann M, Ernemann U, Claussen CD, Pfannenberg C, Pichler BJ, Reimold M, Stegger L. Hybrid PET/MRI of Intracranial Masses: Initial Experiences and Comparison to PET/CT. J Nucl Med 2010; 51(8): 1198–1205.
Afshar-Oromieh A, Haberkorn U, Schlemmer HP, Fenchel M, Eder M, Eisenhut M, Hadaschik BA, Kopp-Schneider A, Röthke M. Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur J Nucl Med Mol Imag 2014; 41(5): 887–897.
Gellén E, Sántha O, Janka E, Juhász I, Péter Z, Erdei I, Lukács R, Fedinecz N, Galuska L, Remenyik É, Emri G. Diagnostic accuracy of 18 F-FDG-PET/CT in early and late stages of high-risk cutaneous malignant melanoma. J Eur Acad Dermatol Venereol 2015; 29(10): 1938–1944.
Veit-Haibach P, Kuhn F, Wiesinger F, Delso G, von Schulthess G. PET–MR imaging using a tri-modality PET/CT–MR system with a dedicated shuttle in clinical routine. Magn Reson Mater Phys, Biol Med 2013; 26(1): 25–35.
Assiri Y, Veit-Haibach P. Contrast-enhanced PET/CT vs. non-contrast enhanced PET/MRI in abdominal oncological lesions-initial results. Eur J Nucl Med Mol I 2012; 39: 189–190.
Schwenzer NF, Schraml C, Müller M, Brendle C, Sauter A, Spengler W, Pfannenberg AC, Claussen CD, Schmidt H. Pulmonary lesion assessment: comparison of whole-body hybrid MR/PET and PET/CT imaging-pilot study. Radiology 2012; 264(2): 551–558.
Stefaan V, Paul KM. PET-MRI: a review of challenges and solutions in the development of integrated multimodality imaging. Phys Med Biol 2015; 60(4): R115–154.
Appenzeller P, Mader C, Schmidt D, Schmid D, Veit-Haibach P. Low-Dose PET/CT vs. Fast Body Coil PET/MRI-How low can you go? Eur J Nucl Med Mol I 2012; 39: S175.
Lee CM, Jeong HJ, Kim EM, Kim DW, Lim ST, Kim HT, Park IK, Jeong YY, Kim JW, Sohn MH. Superparamagnetic iron oxide nanoparticles as a dual imaging probe for targeting hepatocytes in vivo. Magn Reson Med 2009; 62(6): 1440–1446.
Torres Martin de Rosales R, Tavaré R, Paul RL, Jauregui-Osoro M, Protti A, Glaria A, Varma G, Szanda I, Blower PJ. Synthesis of 64CuII–bis (dithiocarbamatebisphosphonate) and its conjugation with superparamagnetic iron oxide nanoparticles: in vivo evaluation as dual-modality PET–MRI agent. Angew Chem Int Ed 2011; 50(24): 5509–5513.
Js C, Park JC, Nah H, Woo S, Oh J, Kim KM, Cheon GJ, Chang Y, Yoo J, Cheon J. A Hybrid Nanoparticle Probe for Dual-Modality Positron Emission Tomography and Magnetic Resonance Imaging. Angew Chem Int Ed 2008; 47(33): 6259–6262.
Chakravarty R, Valdovinos HF, Chen F, Lewis CM, Ellison PA, Luo H, Meyerand ME, Nickles RJ, Cai W. Intrinsically Germanium-69-Labeled Iron Oxide Nanoparticles: Synthesis and In-Vivo Dual-Modality PET/MR Imaging. Adv Mater 2014; 26(30): 5119–5123.
Glaus C, Rossin R, Welch MJ, Bao G. In vivo evaluation of 64Cu-labeled magnetic nanoparticles as a dual-modality PET/MR imaging agent. Bioconj Chem 2010; 21(4): 715–722.
Sharma R, Xu Y, Kim SW, Schueller MJ, Alexoff D, Smith SD, Wang W, Schlyer D. Carbon-11 radiolabeling of iron-oxide nanoparticles for dual-modality PET/MR imaging. Nanoscale 2013; 5(16): 7476–7483.
Zhu J, Zhang B, Tian J, Wang J, Chong Y, Wang X, Deng Y, Tang M, Li Y, Ge C. Synthesis of heterodimer radionuclide nanoparticles for magnetic resonance and single-photon emission computed tomography dual-modality imaging. Nanoscale 2015; 7: 3392–3395.
Huang X, Zhang F, Lee S, Swierczewska M, Kiesewetter DO, Lang L, Zhang G, Zhu L, Gao H, Choi HS. Long-term multimodal imaging of tumor draining sentinel lymph nodes using mesoporous silica-based nanoprobes. Biomaterials 2012; 33: 4370–4378.
Zhang H. 64Cu-DTPA-CLIO-VT680. Molecular Imaging and Contrast Agent Database (MICAD). In Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. National Center for Biotechnology Information (US): Bethesda (MD)2004–2013. Available at: http://www.ncbi.nlm.nih.gov/books/NBK23520/[11 Mar 2008], 2004 2008 Feb 8.
Nahrendorf M, Keliher E, Marinelli B, Leuschner F, Robins CS, Gerszten RE, Pittet MJ, Swirski FK, Weissleder R. Detection of macrophages in aortic aneurysms by nanoparticle PET-CT. Arterioscler Thromb Vasc Biol 2011; 31: 750–757.
Stelter L, Pinkernelle J, Michel R, Schwartländer R, Raschzok N, Morgul M, Koch M, Denecke T, Ruf J, Bäumler H, Jordan A, Hamm B, Sauer I, Teichgräber U. Modification of Aminosilanized Superparamagnetic Nanoparticles: Feasibility of Multimodal Detection Using 3 T MRI, Small Animal PET, and Fluorescence Imaging. Mol Imaging Biol 2010; 12: 25–34.
Ko HY, Lee JH, Kang H, Ryu SH, Song IC, Lee DS, Kim S. A nucleolin-targeted multimodal nanoparticle imaging probe for tracking cancer cells using an aptamer. J Nucl Med 2010; 51: 98–105.
Cui X, Belo S, Krüger D, Yan Y, de Rosales RT, Jauregui-Osoro M, Ye H, Su S, Mathe D, Kovács N. Aluminium hydroxide stabilised MnFe 2 O 4 and Fe 3 O 4 nanoparticles as dual-modality contrasts agent for MRI and PET imaging. Biomaterials 2014; 35: 5840–5846.
Jarrett BR, Correa C, Ma KL, Louie AY. In vivo mapping of vascular inflammation using multimodal imaging. PLoS One 2010; 11(5e13254).
Jarrett BR, Gustafsson B, Kukis DL, Louie AY. Synthesis of (64)Cu-Labeled Magnetic Nanoparticles for Multimodal Imaging. Bioconjug Chem 2008; 19: 1496–1504.
S-m K, Chae MK, Yim MS, Jeong IH, Cho J, Lee C, Ryu EK. Hybrid PET/MR imaging of tumors using an oleanolic acid-conjugated nanoparticle. Biomaterials 2013; 34: 8114–8121.
Hu H, Li D, Liu S, Wang M, Moats R, Conti PS, Li Z. Integrin α 2 β 1 targeted GdVO 4: Eu ultrathin nanosheet for multimodal PET/MR imaging. Biomaterials 2014; 35: 8649–8658.
Aryal S, Key J, Stigliano C, Landis MD, Lee DY, Decuzzi P. Positron emitting magnetic nanoconstructs for PET/MR imaging. Small 2014; 10: 2688–2696.
Yang BY, Moon S-H, Seelam SR, Jeon MJ, Lee Y-S, Lee DS, Chung J-K, Kim YI, Jeong JM. Development of a multimodal imaging probe by encapsulating iron oxide nanoparticles with functionalized amphiphiles for lymph node imaging. Nanomedicine 2015; 10: 1899–1910.
Locatelli E, Gil L, Israel LL, Passoni L, Naddaka M, Pucci A, Reese T, Gomez-Vallejo V, Milani P, Matteoli M, Llop J, Lellouche JP, Franchini MC. Biocompatible nanocomposite for PET/MRI hybrid imaging. Int J Nanomed 2012; 7: 6021–6033.
Fan Q, Cheng K, Hu X, Ma X, Zhang R, Yang M, Lu X, Xing L, Huang W, Gambhir SS. Transferring Biomarker into Molecular Probe: Melanin Nanoparticle as a Naturally Active Platform for Multimodality Imaging. J Am Chem Soc 2014; 136: 15185–15194.
Moon S-H, Yang BY, Kim YJ, Hong MK, Lee Y-S, Lee DS, Chung J-K, Jeong JM. Development of a complementary PET/MR dual-modal imaging probe for targeting prostate-specific membrane antigen (PSMA). Nanomed Nanotechnol Biol Med 2016; 12: 871–879.
Tu C, Ng TS, Jacobs RE, Louie AY. Multimodality PET/MRI agents targeted to activated macrophages. J Biol Inorg Chem 2014; 19: 247–258.
